These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 12006916)
1. Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol. van Dam M; van Wissen S; Kastelein JJ J Cardiovasc Risk; 2002 Apr; 9(2):89-95. PubMed ID: 12006916 [TBL] [Abstract][Full Text] [Related]
2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
3. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Malhotra HS; Goa KL Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Boden WE Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126 [TBL] [Abstract][Full Text] [Related]
5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
6. Lipid-lowering treatment in coronary artery disease: how low should cholesterol go? Jones PH Drugs; 2000 May; 59(5):1127-35. PubMed ID: 10852644 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. Hunninghake DB Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501 [TBL] [Abstract][Full Text] [Related]
9. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Goa KL; Barradell LB; Plosker GL Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820 [TBL] [Abstract][Full Text] [Related]
10. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER). Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705 [TBL] [Abstract][Full Text] [Related]
11. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
12. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D; Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002 [TBL] [Abstract][Full Text] [Related]
13. What does the future hold for diabetic dyslipidaemia? Crespin SR Acta Diabetol; 2001; 38 Suppl 1():S21-6. PubMed ID: 11829450 [TBL] [Abstract][Full Text] [Related]
14. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. Ansell BJ; Watson KE; Fogelman AM JAMA; 1999 Dec; 282(21):2051-7. PubMed ID: 10591388 [TBL] [Abstract][Full Text] [Related]
15. The importance of aggressive lipid management in patients at risk: evidence from recent clinical trials. Ferdinand KC Clin Cardiol; 2004 Jun; 27(6 Suppl 3):III12-5. PubMed ID: 15239486 [TBL] [Abstract][Full Text] [Related]
16. Managing dyslipidemia in the high-risk patient. Stein EA Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720 [TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy of dyslipidemia. McKenney JM Cardiovasc Drugs Ther; 2001 Sep; 15(5):413-22. PubMed ID: 11855660 [TBL] [Abstract][Full Text] [Related]
18. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484 [TBL] [Abstract][Full Text] [Related]
19. Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors. Lopez LM Am J Health Syst Pharm; 2002 Jun; 59(12):1173-9; quiz 1180-2. PubMed ID: 12073858 [TBL] [Abstract][Full Text] [Related]
20. Niacin as a component of combination therapy for dyslipidemia. Miller M Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]